PI Industries reported Q1 FY27 revenue of Rs 1,702 crore and EBITDA of Rs 369 crore. The company faces challenges in its export segment but sees growth in biologicals. Investments in new products and CRDMO platforms are ongoing.
PI Industries Q1 FY27 Performance Update
PI Industries reported Q1 FY27 revenue of Rs. 17,023 million (approx. Rs. 1,702.3 crore) and EBITDA of Rs. 3,693 million (approx. Rs. 369.3 crore), with an EBITDA margin of 22%. The company continues its investment in R&D, dedicating 3-4% of revenue to new growth platforms. Reader Takeaway: Navigating export headwinds while investing in future growth drivers. ## What just happened PI Industries announced its financial results for the first quarter of Fiscal Year 2027. The company posted revenue of Rs. 1,702.3 crore and EBITDA of Rs. 369.3 crore. The quarter was marked by mixed performance across its business segments. ## Why this matters These results indicate how PI Industries is performing in the current economic climate, especially concerning global agrochemical market conditions and its strategic investments in new business areas like Pharma/CRDMO and Biologicals. Investors will assess the company's ability to manage challenges and leverage growth opportunities. ## The backstory PI Industries is a key player in the agrochemical sector, offering manufacturing solutions for global innovators and also marketing its own brands domestically. The company has been strategically expanding into newer areas like Contract Research, Development, and Manufacturing Organization (CRDMO) services and biological crop protection solutions to diversify its revenue streams and tap into higher-growth segments. ## What changes now The company is pushing forward with new product launches, such as the awaiting regulatory approval for insecticide Pioxaniliprole and planned launch of Dicloromezotiaz. Investments in the Pharma/CRDMO and Biologicals segments continue, with management anticipating these to contribute to revenue in the future despite current upfront costs impacting short-term profitability. ## Risks to watch Key concerns include the ongoing contraction in the global crop protection industry, which affects the export segment. Additionally, significant upfront investments in biological and pharma businesses are impacting short-term profits, and their path to profitability needs monitoring. Dependence on regulatory approvals for new products like Pioxaniliprole is also a factor. ## Peer comparison While specific peer comparisons are not provided in the filing, PI Industries operates in a competitive landscape alongside other Indian agrochemical companies and global crop protection majors. Its performance in the domestic market will be compared against local players, while its export segment faces competition from established international chemical manufacturers. ## Context metrics (time-bound) * **Revenue:** Rs. 17,023 million in Q1 FY27. * **EBITDA:** Rs. 3,693 million in Q1 FY27. * **EBITDA Margin:** 22% in Q1 FY27. * **Gross Margin:** 57% in Q1 FY27. * **Net Cash:** Rs. 38 billion. * **Order Book:** USD 1.2 billion. * **Domestic Business Volume Growth:** 12% in Q1 FY27. * **Capex:** Rs. 250 crore in Q1 FY27; guidance of Rs. 700-800 crore for FY27. * **Working Capital Reduction:** 19 days, releasing Rs. 300 crore. ## What to track next Investors will be watching for regulatory approvals on new products, the progress and potential break-even timelines for the Pharma/CRDMO and Biologicals segments, and a potential recovery in the export business during the second half of FY27. The execution of the full-year capex plan and working capital management will also be key.
